Abe H, Sako H, Umeda T, Eguchi Y, Okino K, Terata N, Kodama M
First Dept. of Surgery, Shiga University of Medical Science, Japan.
Gan To Kagaku Ryoho. 1996 Jul;23(8):1049-54.
In a recent 14-year period from December 1978 to December 1993, 180 patients with breast cancer were treated at the hospital, and out of these 180 patients, 38 patients (21.1%) who had a recurrent breast cancer were clinically evaluated. The first recurrence occurred in the local skin in 13 patients, regional lymph node in 1, bone in 13, lung in 4, liver in 4 and in other areas in 3. Histologically, the incidence of scirrhous carcinoma recurrence was higher than that of papillotubular carcinomas. There was no recurrence in mucinous carcinomas. The frequency of recurrence became higher in accordance with TNM classification, namely, 6.7% in Stage I, 23.7% in Stage II, 37.5% in Stage IIIa, and 47.1% in Stage IIIb cancers. An increasing tendency in the recurrence rate was also noted with an increase of tumor diameter or lymph node metastasis. Otherwise, there was no difference in cumulative survival after recurrence between TNM classification. There were no correlations between the estrogen receptor and incidence of recurrence or 5-year survival rate. The disease free interval (DFI) was less than 2 years in about 60% of the recurrent cases. DFI of bone metastasis was longer than for the other sites of recurrence. The survival rate increased according to prolongation of DFI. After through evaluation of these results, one should pay close attention to follow-up after mastectomy.
在1978年12月至1993年12月这一最近的14年期间,该医院共治疗了180例乳腺癌患者,在这180例患者中,对38例(21.1%)复发性乳腺癌患者进行了临床评估。首次复发发生在局部皮肤的有13例,区域淋巴结1例,骨13例,肺4例,肝4例,其他部位3例。组织学上,硬癌复发的发生率高于乳头状管状癌。黏液癌未出现复发。根据TNM分期,复发频率升高,即I期为6.7%,II期为23.7%,IIIa期为37.5%,IIIb期为47.1%。复发率也随肿瘤直径或淋巴结转移的增加而呈上升趋势。此外,TNM分期之间复发后的累积生存率没有差异。雌激素受体与复发发生率或5年生存率之间没有相关性。约60%的复发病例无病生存期(DFI)小于2年。骨转移的DFI长于其他复发部位。生存率随DFI的延长而提高。在对这些结果进行全面评估后,应密切关注乳房切除术后的随访。